Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CGTX 
Cognition Therapeutics Inc (CGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: CGTX (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.81M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 4 | Beta 1.25 | 52 Weeks Range 0.22 - 3.83 | Updated Date 02/25/2026 |
52 Weeks Range 0.22 - 3.83 | Updated Date 02/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.47 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -78.99% | Return on Equity (TTM) -109.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 115885152 | Price to Sales(TTM) - |
Enterprise Value 115885152 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.44 | Shares Outstanding 88274258 | Shares Floating 81446244 |
Shares Outstanding 88274258 | Shares Floating 81446244 | ||
Percent Insiders 2.27 | Percent Institutions 23.86 |
Upturn AI SWOT
Cognition Therapeutics Inc
Company Overview
History and Background
Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to treat serious diseases of the brain. The company was founded in 2007 and has since been dedicated to addressing unmet medical needs in neurodegenerative diseases. A significant milestone was the advancement of its lead drug candidate, CT1812, into clinical trials for Alzheimer's disease and Lewy body dementia.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Cognition Therapeutics Inc. focuses on the discovery and development of novel small molecule drugs to treat neurodegenerative diseases. Their primary approach targets synaptic repair and cognitive restoration.
Leadership and Structure
Cognition Therapeutics Inc. is led by a management team with expertise in drug development and neuroscience. The organizational structure is typical of a clinical-stage biopharmaceutical company, with teams dedicated to research and development, clinical operations, regulatory affairs, and business development. Specific leadership roles and the exact organizational chart are not publicly detailed in a way that can be easily summarized here.
Top Products and Market Share
Key Offerings
- Product Name 1: CT1812 - A sigma-1 receptor chaperone designed to normalize synaptic function and reverse cognitive decline in neurodegenerative diseases. This is their lead candidate. Market share data is not applicable as it is in clinical development. Competitors include companies developing drugs for Alzheimer's and Lewy Body Dementia, such as Eisai (Lecanemab), Biogen (Aducanumab), and numerous others in early to late-stage development.
Market Dynamics
Industry Overview
The neurodegenerative disease therapeutics market is a rapidly growing and highly competitive sector, driven by an aging global population and the significant unmet medical need for effective treatments. The Alzheimer's disease market, in particular, is substantial and is seeing increased investment and innovation, though challenges remain in demonstrating efficacy and gaining broad market adoption.
Positioning
Cognition Therapeutics Inc. is positioned as a developer of novel, mechanism-of-action therapeutics targeting synaptic repair, which differentiates them from many competitors focusing solely on amyloid or tau clearance. Their focus on cognitive restoration offers a distinct value proposition.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease therapeutics alone is projected to reach tens of billions of dollars annually. Cognition Therapeutics Inc. is positioned to capture a segment of this market if CT1812 demonstrates significant efficacy in clinical trials. The broader market for neurodegenerative diseases is even larger.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action targeting synaptic repair.
- Experienced management team in drug development.
- Potential to address a significant unmet medical need.
- Focus on cognitive restoration.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Significant funding requirements for further development.
- Limited historical financial performance data as a public entity.
Opportunities
- Growing market demand for neurodegenerative disease treatments.
- Potential for strategic partnerships and licensing deals.
- Advancements in neuroscience research and understanding.
- Expanding indications for their therapeutic approach.
Threats
- High failure rates in clinical trials for neurodegenerative diseases.
- Intense competition from established and emerging biopharmaceutical companies.
- Regulatory hurdles and evolving approval pathways.
- Uncertainty in reimbursement and market access for new therapies.
Competitors and Market Share
Key Competitors
- Eisai Co., Ltd. (ESALY)
- Biogen Inc. (BIIB)
- Eli Lilly and Company (LLY)
Competitive Landscape
Cognition Therapeutics Inc. faces intense competition from large pharmaceutical companies and smaller biotechs developing treatments for neurodegenerative diseases. Their advantage lies in their novel synaptic repair mechanism, but they must overcome the established players' resources and pipeline depth.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Cognition Therapeutics Inc. has been characterized by advancements in its preclinical and clinical pipelines, successful fundraising rounds, and strategic collaborations. This growth is measured by scientific progress and corporate development rather than revenue.
Future Projections: Future projections for Cognition Therapeutics Inc. are contingent on the success of CT1812 in ongoing and future clinical trials. Analyst projections would likely focus on potential market penetration and future revenue streams if their lead candidate receives regulatory approval.
Recent Initiatives: Recent initiatives would likely include the progression of CT1812 through clinical trial phases, potential new drug discoveries, and strategic partnerships to advance pipeline development.
Summary
Cognition Therapeutics Inc. is a promising clinical-stage biopharmaceutical company focused on novel neurodegenerative disease treatments. Its strength lies in its innovative approach to synaptic repair, addressing a critical unmet need. However, like all clinical-stage companies, it faces significant risks associated with clinical trial outcomes and requires substantial funding to advance its pipeline. Careful monitoring of trial results and competitive advancements is crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial News Outlets
- Industry Analysis Reports
- Company Investor Relations Websites
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data for clinical-stage companies is not applicable until product launch.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cognition Therapeutics Inc
Exchange NASDAQ | Headquaters Purchase, NY, United States | ||
IPO Launch date 2021-10-08 | CEO, President & Director Ms. Lisa Ricciardi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://www.cogrx.com |
Full time employees 25 | Website https://www.cogrx.com | ||
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.